Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Safety, and Efficacy of Cedirogant (ABBV-157) in Healthy Volunteers and Psoriasis
NCT03922607Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Jun 2019
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cedirogant in plaque psoriasis (5 arms), sponsored by AbbVie Inc. Primary endpoints: Maximum Plasma Concentration (Cmax) of ABBV-157 at 28 days, Time to Maximum Plasma Concentration (Tmax) of ABBV-157 at 28 days and 9 more. Started Jun 2019; status: completed.
02
Drugs
cedirogant
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03922607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03922607.